Finance

Beta
Lists
234080:KRX
JW Life Science Corp
₩11,410.00
+2.06%
(+230.00) 1D
Jun 12, 3:30:10 PM GMT+9  ·   KRW
All symbols
SymbolPriceChange% Change
Generating top insights for 234080...
Open
₩11,180
High
₩11,540
Low
₩11,180
Mkt. cap
180.67B
Avg. vol.
44.81K
Volume
0.00
Dividend
4.82%
Quarterly dividend
₩137
Ex-dividend date
Mar 31, 2026
P/E ratio
6.05
52-wk high
₩15,580
52-wk low
₩10,600
EPS
₩1,885
Shares outstanding
15.83M
No. of employees
297
Open
₩11,180
High
₩11,540
Low
₩11,180
Mkt. cap
180.67B
Avg. vol.
44.81K
Volume
0.00
Dividend
4.82%
Quarterly dividend
₩137
Ex-dividend date
Mar 31, 2026
P/E ratio
6.05
52-wk high
₩15,580
52-wk low
₩10,600
EPS
₩1,885
Shares outstanding
15.83M
No. of employees
297
News stories
From sources across the web
About JW Life Science Corp
CEO-
Employees297
Founded1994
Headquarters-
SectorPharmaceutical industry
Websitejw-lifescience.co.kr
Previous reportsAll values in KRW
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in KRW
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
62.26B
62.61B
64.33B
63.52B
Cost of goods sold
43.20B
45.73B
46.14B
44.77B
Cost of revenue
43.20B
45.73B
46.14B
44.77B
Research and development expenses
1.27B
1.44B
1.50B
1.26B
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
7.49B
7.65B
8.35B
7.45B
Operating expense
9.68B
9.81B
10.61B
9.43B
Total operating expenses
52.88B
55.53B
56.75B
54.20B
Operating income
9.38B
7.08B
7.58B
9.32B
Other non operating income
-92.07M
-814.80M
1.44B
-277.99M
EBT including unusual items
9.29B
6.26B
7.43B
9.05B
EBT excluding unusual items
9.29B
6.26B
7.38B
9.05B
Income tax expense
-1.89B
1.40B
973.16M
2.36B
Effective tax rate
-20.35%
22.29%
13.10%
26.08%
Other operating expenses
73.54M
106.17M
78.22M
77.94M
Net income
11.18B
4.87B
6.45B
6.69B
Net profit margin
17.96%
7.77%
10.03%
10.53%
Earnings per share
-
-
-
-
Interest and investment income
-
-
610.42M
-
Interest expense
-
-
-2.84B
-
Net interest expenses
-
-
-2.23B
-
Depreciation and amortization charges
277.73M
285.42M
279.05M
291.76M
EBITDA
14.11B
11.55B
12.30B
14.03B
Gain or loss from assets sale
-87.59M
44.00K
4.11M
1.00K
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer